Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)
Information source: Fundación Lindavista del Corazón AC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: valsartan (Drug); pravastatin (Drug); simvastatin (Drug); ezetimibe (+) simvastatin (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Fundación Lindavista del Corazón AC Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.
Summary
Evaluate pleiotropic effects of simvastatin in hypertensive patients.
Clinical Details
Official title: Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Females Or Males Over 18 Years Old
- Patients With Systemic Arterial Hypertension Grade I And II According With The
European Society Of Cardiology
- Left Ventricular hypertrophy Demonstrated By Echocardiography
- Mild To Moderated hypercholesterolemia
- Willing To Participate And Sign The Informed Consent Form (ICF)
Exclusion Criteria:
- Type 1 Or 2 Diabetes Mellitus
- Familiar hypercholesterolemia
- Low Density Lipoprotein-Cholesterol (LDL-C) > 190 mg/dl
- History Of Myocardial Infarction Or Stable Chronic Angina
- Triglycerides >250 mg/dl
Locations and Contacts
Additional Information
Starting date: January 2008
Last updated: August 17, 2013
|
